ArticleThe Journal of clinical investigation1995
Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture.
Article in The Journal of clinical investigation, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 110 citations in OpenAlex.
- Pooled it
- Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies.British journal of haematology · 2010Trial
- Blockade of endothelin-1 receptor B regulates molecules of the major histocompatibility complex in sickle cell disease.Frontiers in immunology · 2023Article
- Magnesium homeostasis in deoxygenated sickle erythrocytes is modulated by endothelin-1 via NaFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022Article
- Red blood cell distribution width is associated with increased interactions of blood cells with vascular wall.Scientific reports · 2022Article
- Endothelin A receptor antagonist attenuated renal iron accumulation in iron overload heme oxygenase-1 knockout mice.Canadian journal of physiology and pharmacology · 2022Article
- Multiple inducers of endothelial NOS (eNOS) dysfunction in sickle cell disease.American journal of hematology · 2021Review
- Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy.Journal of clinical medicine · 2020Review
- The multifaceted role of ischemia/reperfusion in sickle cell anemia.The Journal of clinical investigation · 2020Review
- Epidemiology, Pathogenesis, and Clinical Approach in Group 5 Pulmonary Hypertension.Frontiers in medicine · 2020Review
- Red Blood Cells: Chasing Interactions.Frontiers in physiology · 2019Review
- Investigational use of PEGylated carboxyhemoglobin bovine in a Jehovah's Witness with hemorrhagic shock.Transfusion · 2018Article
- Endothelin-A Receptor Antagonism Retards the Progression of Murine Sickle Cell Nephropathy.Journal of the American Society of Nephrology : JASN · 2017Article
- The endothelin B receptor plays a crucial role in the adhesion of neutrophils to the endothelium in sickle cell disease.Haematologica · 2017Article
- Endothelin receptor antagonists in sickle cell disease: A promising new therapeutic approach.Life sciences · 2016Review
- Endothelin.Pharmacological reviews · 2016Review
- Endothelin-1 contributes to the progression of renal injury in sickle cell disease via reactive oxygen species.British journal of pharmacology · 2016Article
- Endothelin-1 induced desensitization in primary afferent neurons.Neuroscience letters · 2014Article
- Evidence for the endothelin system as an emerging therapeutic target for the treatment of chronic pain.Journal of pain research · 2014Review
- Experience with the use of Hemopure in the care of a massively burned adult.International journal of burns and trauma · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The molecular defect in sickle cell disease resides in the beta globin gene, with consequent defects in erythrocytes only, suggesting that the vascular occlusion and vasomotor instability which characterize this disease are the result of interactions between abnormal sickle erythrocytes and cells of the blood vessel wall. We explored whether sickle erythrocytes may have effects on vascular tone, exclusive of adhesion events. Exposure of human endothelial cells in culture to previously sickled sickle erythrocytes resulted in a four to eight-fold transcriptional induction of the gene encoding the potent vasoconstrictor endothelin-1 (ET-1). Unsickled sickle erythrocytes or normal erythrocytes exposed to "sickling" conditions had no effect on ET-1 gene induction. Contact of the sickled erythrocytes with the endothelium was not required. Elevations in the ET-1 transcript peaked at 3 h after exposure and persisted for up to 24 h. Four to sixfold increases in the amount of ET-1 peptide was released into the medium surrounding the endothelial cells after exposure to sickled sickle erythrocytes. This is the first demonstration of the regulation of gene expression in endothelial cells as a result of interaction with sickle cells, with induction of genes encoding vasoconstrictors. Furthermore, these findings suggest that sickle erythrocytes may have the capacity to affect local vasomotor tone directly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.